Sadie Stern Sells 4,259 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern sold 4,259 shares of the stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Sadie Stern also recently made the following trade(s):

• On Monday, September 9th, Sadie Stern sold 426 shares of DexCom stock. The stock was sold at an average price of $69.15, for a total value of $29,457.90.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $72.83 on Friday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The stock has a market capitalization of $28.45 billion, a P/E ratio of 43.61, a P/E/G ratio of 2.28 and a beta of 1.17. The business has a 50-day moving average price of $70.61 and a two-hundred day moving average price of $89.83.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on DXCM. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Barclays dropped their target price on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. Leerink Partners decreased their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Royal Bank of Canada cut their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, Raymond James reduced their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

Institutional Investors Weigh In On DexCom

Institutional investors and hedge funds have recently modified their holdings of the business. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in DexCom during the 2nd quarter worth $25,000. Sachetta LLC grew its stake in shares of DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the period. Crewe Advisors LLC bought a new stake in DexCom in the first quarter valued at about $29,000. Riverview Trust Co lifted its stake in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares during the period. Finally, DT Investment Partners LLC boosted its holdings in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after buying an additional 315 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.